| Symbol | EVMN |
|---|---|
| Name | EVOMMUNE, INC. |
| Sector | UNDEFINED |
| Region | UNDEFINED |
| Industry | Pharmaceutical Preparations |
| Address | 1841 PAGE MILL ROAD,SUITE 100, PALO ALTO, California, 94304, United States |
| Telephone | +1 925 247-4487 |
| Fax | — |
| — | |
| Website | — |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0002044725 |
| Description | Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis and ulcerative colitis. Among our portfolio of programs, we currently have two product candidates, EVO756 and EVO301, in Phase 2 trials. We are initially developing EVO756 for the treatment of CSU and AD, and EVO301 for the treatment of AD and UC. We see broad expansion potential for both programs across additional chronic inflammatory diseases. We also intend to advance additional preclinical programs into clinical development. Additional info from NASDAQ: |
Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights
Read more(90% Positive) EVOMMUNE, INC. (EVMN) Announces Enrollment Update for expected Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment
Read moreEvommune Initiates Phase 2b Clinical Trial of MRGPRX2 Inhibitor EVO756 in Migraine Prophylaxis
Read moreNew Form SCHEDULE 13G - Evommune, Inc. <b>Filed:</b> 2026-07-16 <b>AccNo:</b> 0000919574-26-004453 <b>Size:</b> 17 KB
Read moreCarver Kyle 🟢 acquired 1.0K shares of Evommune, Inc. (EVMN) at $13.26 Transaction Date: Jul 08, 2026 | Filing ID: 000007
Read more(90% Positive) EVOMMUNE, INC. (EVMN) Announces Enrollment Update for patients Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment
Read moreEvommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria
Read moreNew Form 424B3 - Evommune, Inc. <b>Filed:</b> 2026-06-29 <b>AccNo:</b> 0001193125-26-286924 <b>Size:</b> 93 KB
Read moreDrew Janice Suzann 🟡 adjusted position in 20.0K shares (2 derivative) of Evommune, Inc. (EVMN) at $22.63 Transaction Date: Jun 22, 2026 | Filing ID: 000005
Read morePatel Jeegar Pravinkumar 🟡 adjusted position in 1.5K shares (1 derivative) of Evommune, Inc. (EVMN) at $22.50 Transaction Date: Jun 22, 2026 | Filing ID: 000007
Read more